Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy
| Autor: | Koichi Azuma, Norikazu Matsuo, Takaaki Tokito, Akihiko Kawahara, Tomoaki Hoshino, Hidenobu Ishii |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment chemistry.chemical_element Antineoplastic Agents Antibodies Monoclonal Humanized B7-H1 Antigen Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Refractory Atezolizumab Internal medicine PD-L1 Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) neoplasms Etoposide Aged Retrospective Studies Pharmacology Chemotherapy biology business.industry Retrospective cohort study Middle Aged Small Cell Lung Carcinoma humanities respiratory tract diseases 030104 developmental biology chemistry 030220 oncology & carcinogenesis biology.protein Female Platinum business medicine.drug |
| Zdroj: | Investigational new drugs. 39(1) |
| ISSN: | 1573-0646 |
| Popis: | Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab plus carboplatin and etoposide in SCLC patients previously treated with platinum-based chemotherapy. We retrospectively screened consecutive eight SCLC patients who received atezolizumab plus carboplatin and etoposide after platinum-based chemotherapy. We evaluated the efficacy of this treatment and its association with programmed cell death-ligand 1 (PD-L1) expression. Three and five patients had sensitive relapse and refractory relapse for first-line platinum-based chemotherapy, respectively. The overall response rate and disease control rate was 37.5% and 75.0%, respectively. Median progression-free survival was 4.0 months. Out of three patients who achieved clinical response, two patients had refractory relapse for first-line platinum-based chemotherapy. No patient exhibited PD-L1 expression. Atezolizumab plus carboplatin and etoposide therapy was effective in SCLC patients with sensitive and refractory relapse and might be a second-line treatment option for SCLC patients previously treated with platinum-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink